The Supreme Court of the United States will hear arguments in a case seeking to invalidate the patents on the BRCA1 and BRCA2 mutations. The patent-holder, Myriad Laboratories, owns patents on the genetic mutations themselves. The Alliance has joined the suit, led by the ACLU.
Read the ACLU’s press release here
OCRA recently joined the Inter-Organization Cancer Genetics Clinical Evidence Coalition (INTERACT), which is working to ensure genetic testing access for all who may carry inherited mutations that increase the risk … Continued
International Forum on Ovarian Cancer Aims to Accelerate Progress Ovarian Cancer Research Alliance (OCRA) President and CEO Audra Moran, along with members of the OCRA team, joined leading scientists and … Continued
Closing out 2024 and Looking Ahead to 2025 As we approach the close of this year’s legislative calendar, the urgency surrounding the federal budget process cannot be overstated. If action … Continued
Get email updates about research news, action alerts, and ways to join the fight.
